Wall Street analysts expect Puma Biotechnology Inc (NASDAQ:PBYI) to announce earnings per share (EPS) of ($2.04) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Puma Biotechnology’s earnings. The highest EPS estimate is ($1.97) and the lowest is ($2.15). Puma Biotechnology reported earnings per share of ($1.22) during the same quarter last year, which indicates a negative year-over-year growth rate of 67.2%. The business is scheduled to issue its next quarterly earnings results on Wednesday, March 7th.

On average, analysts expect that Puma Biotechnology will report full-year earnings of ($8.19) per share for the current fiscal year, with EPS estimates ranging from ($8.31) to ($8.11). For the next fiscal year, analysts anticipate that the company will post earnings of ($5.15) per share, with EPS estimates ranging from ($5.85) to ($3.62). Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Puma Biotechnology.

Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) EPS for the quarter, topping the consensus estimate of ($2.50) by $0.43. The company had revenue of $6.10 million for the quarter, compared to analyst estimates of $3.78 million. During the same quarter last year, the business posted ($1.11) earnings per share.

A number of research firms have recently issued reports on PBYI. J P Morgan Chase & Co reiterated a “buy” rating and issued a $131.00 price objective on shares of Puma Biotechnology in a report on Wednesday, October 4th. Bank of America reaffirmed a “buy” rating and set a $135.00 price objective (up from $117.00) on shares of Puma Biotechnology in a research report on Monday, October 9th. Barclays reaffirmed a “buy” rating and set a $122.00 price objective (up from $103.00) on shares of Puma Biotechnology in a research report on Friday, November 10th. Credit Suisse Group lifted their price objective on shares of Puma Biotechnology from $136.00 to $142.00 and gave the stock an “outperform” rating in a research report on Friday, November 10th. Finally, Royal Bank Of Canada reduced their price objective on shares of Puma Biotechnology from $108.00 to $92.00 and set a “sector perform” rating for the company in a research report on Friday, November 10th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $130.67.

In other Puma Biotechnology news, SVP Richard Paul Bryce sold 15,000 shares of the stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $120.00, for a total transaction of $1,800,000.00. Following the transaction, the senior vice president now directly owns 42,239 shares in the company, valued at approximately $5,068,680. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Charles R. Eyler sold 1,322 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $105.46, for a total value of $139,418.12. The disclosure for this sale can be found here. Insiders own 21.10% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. Strs Ohio bought a new position in shares of Puma Biotechnology during the 2nd quarter worth $122,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Puma Biotechnology in the 2nd quarter valued at about $146,000. Kazazian Asset Management LLC purchased a new stake in shares of Puma Biotechnology in the 2nd quarter valued at about $209,000. Teacher Retirement System of Texas purchased a new stake in shares of Puma Biotechnology in the 2nd quarter valued at about $211,000. Finally, Ameritas Investment Partners Inc. raised its holdings in shares of Puma Biotechnology by 5.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,522 shares of the biopharmaceutical company’s stock valued at $220,000 after acquiring an additional 140 shares in the last quarter. 96.05% of the stock is owned by hedge funds and other institutional investors.

Shares of Puma Biotechnology (NASDAQ:PBYI) opened at $100.75 on Monday. Puma Biotechnology has a fifty-two week low of $28.35 and a fifty-two week high of $136.90.

COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Anticipate Puma Biotechnology Inc (PBYI) to Post -$2.04 Earnings Per Share” was reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/12/11/zacks-analysts-anticipate-puma-biotechnology-inc-pbyi-to-post-2-04-earnings-per-share.html.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Get a free copy of the Zacks research report on Puma Biotechnology (PBYI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.